Athira Pharma announces publication of preclinical data on fosgonimeton

Athira Pharma announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease. The original research article, “Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics. “These data continue to highlight the potential of fosgonimeton as a novel therapeutic approach for Alzheimer’s disease targeting multiple facets of its complex pathophysiology,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira. “By positively modulating the HGF signaling system, fosgonimeton demonstrated neuroprotective and neurotrophic effects, countering mechanisms of amyloid-beta (Abeta)-induced toxicity both in vitro and in vivo. Our preclinical findings describe several mechanisms by which fosgonimeton may disrupt the neurodegenerative cascade of Alzheimer’s disease downstream of Abeta toxicity, including reduction of mitochondrial oxidative stress and excitotoxicity, improvement of autophagic pathway function, and attenuation of tau hyperphosphorylation.”